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Abstract 
 
Purpose: The purpose of this study was to quantitatively evaluate the visibility and artifacts of 
commercially available fiducial markers in order to optimize their selection for image-guided 
stereotactic body radiation therapy (SBRT). 
 
Methods and Materials: From six different vendors, we selected 11 fiducials commonly used in 
image-guided radiation therapy (IGRT); the fiducials varied in material composition (gold, 
platinum, carbon), shape (cylindrical, notched/linear, coiled, ball-like, step), and size measured 
in terms of diameter (0.28-1.0 mm) and length (3.0-20.0 mm). Each fiducial was centered in 4-
mm bolus within a 13-cm-thick water-equivalent phantom. Fiducials were imaged with use of a 
simulation computed tomography (CT) scanner, a CT-on-rails system, and an onboard cone-
beam CT system. Acquisition parameters were set according to clinical protocols. Visibility was 
assessed in terms of contrast (ΔHU) and the Michelson visibility metric. Artifacts were 
quantified in terms of relative standard deviation and relative streak artifacts level (rSAL). 
Twelve radiation oncologists ranked each fiducial in terms of clinical usefulness. 
 
Results: Contrast and artifacts increased with fiducial size. For CT imaging, maximum contrast 
(2722 HU) and artifacts (rSAL = 2.69) occurred for the largest-diameter (0.75 mm) platinum 
fiducial. Minimum contrast (551 HU) and reduced artifacts (rSAL = 0.65) were observed for the 
smallest-diameter (0.28 mm) gold fiducial. Carbon produced the least severe artifacts (rSAL = 
0.29). The survey indicated that physicians preferred gold fiducials with a 0.35- to 0.43-mm 
diameter, 5- to 10-mm length, and a coiled or cylindrical shape that balanced contrast and 
artifacts. 
 
Conclusions: We evaluated 11 different fiducials in terms of visibility and artifacts. The results 
of this study may assist radiation oncologists who seek to maximize contrast, minimize artifacts, 
and/or balance contrast versus artifacts by fiducial selection. 
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Introduction 
Stereotactic body radiation therapy (SBRT) involves delivering conformal high doses (≥5 Gy per 
fraction) of radiation over a reduced number of fractions (≤5) to body sites outside the central 
nervous system (1). SBRT is used for various cancer types in which ablative local doses are 
limited by nearby organs at risk (OARs) (2, 3). SBRT has demonstrated excellent local control 
and overall survival results in early-stage lung cancer, and its use is growing in popularity for 
other cancer types including prostate, pancreatic, renal, and adrenal cancers, in addition to 
oligometastatic disease (4-6). To achieve the high biologically effective target dose required for 
SBRT, treatment planning makes use of sharp dose falloff and tight planning target volume 
margins to minimize normal tissue toxicity. Volumetric imaging using cone-beam CT (CBCT), 
CT-on-rails (CTOR), or magnetic resonance imaging (MRI) prior to treatment is thus a necessity 
to visualize changes in soft tissue anatomy relative to planning target volumes.  
Low-contrast lesions in the liver or pancreas are not easily visualized in CBCT images. 
To overcome this obstacle, high-contrast fiducials are often implanted into or nearby low-
contrast gastrointestinal (GI) tumors under endoscopic ultrasound (EUS) guidance to serve as 
surrogates of tumor position (7, 8). During treatment setup, the fiducial markers help localize the 
tumor in the CBCT image. Even with CTOR, although OARs may be more easily visualized, 
intravenous contrast is not administered at the time of daily treatments, which may make 
isodense tumors impossible to visualize.  
Many different types of fiducials of various shapes, sizes, and materials are available for 
implantation. The visualization of some fiducials can be more difficult than others due to 
differences in image artifacts and fiducial contrast (9, 10). Optimal fiducial selection requires 
consideration of the tradeoff between contrast and image artifacts, as well as clinical 
considerations such as the probability of fiducial migration and treatment modality (e.g., photons 
versus protons). Fiducial contrast is dominated by the x-ray energy spectrum and linear 
attenuation coefficient that is a function of the fiducial composition. Photoelectric absorption is 
the dominant photon interaction in the diagnostic energy range (keV) responsible for image 
contrast and varies as the cube of the atomic number of the attenuating medium. Conversely, 
high atomic number materials such as metal fiducials generate streak artifacts in x-ray CT 
images. Image artifacts may obscure low-contrast lesions, thereby increasing uncertainty during 
contour delineation or reducing setup accuracy before treatment delivery. Furthermore, artifacts 
in CT simulation images may introduce dosimetric errors during the treatment planning stage 
that are particularly concerning for proton therapy (11). 
Currently, only a few studies have investigated the contrast and artifacts observed with 
CT imaging of the fiducials available for GI radiotherapy applications. Chan et al. (12) 
investigated six gold markers and one polymer marker and concluded that gold markers are 
visible in CT, CBCT, ultrasound, and 2D kV portal imaging, but the results were strictly 
qualitative. Handsfield et al. (13) performed a quantitative investigation of visibility and artifacts 
for gold, carbon, and polymer fiducials. Only fiducials from a single vendor and a cylindrical 
shape were considered. Platinum fiducials were also not considered, which may be of interest for 
clinics that use MRI-to-CT image fusion as part of the treatment planning process. Nair et al. 
(14) showed that the contrast of platinum fiducials implanted in liver tissue was significantly 
superior to gold seeds or coils when imaged with MRI. The purpose of this study was to provide 
a quantitative evaluation of fiducial visibility and artifacts to optimize fiducial selection for 
clinical applications, primarily in isodense GI cancers near OARs. 
 
Methods and Materials 
Fiducial markers 
Fiducial visibility and image artifacts were evaluated for 11 different fiducial markers selected 
from six vendors. Only fiducials suitable for implantation in the pancreas by EUS-guided 
placement were considered. The fiducials varied in terms of material composition (gold, 
platinum, carbon), shape (cylindrical, notched/linear, coiled, ball-like, step), and size measured 
in terms of diameter (0.28-1.0 mm) and length (3.0-20.0 mm). Carbon was considered since 
patients originally planned to receive proton radiation therapy (RT) may alternatively receive 
external photon beam RT after fiducial placement due to insurance or clinical considerations. 
Table 1 summarizes the relevant fiducial properties. The Gold Anchor fiducials, listed twice, 
have notches every 2 mm that allow the fiducials to be folded into a “ball-like” shape or placed 
as a “line” during implantation. The final configuration depends on tumor resistance and 
insertion technique. 
Table 1 Fiducial marker types and properties 
Manufacturer  Fiducial name Material 
Fiducial 
shape 
Diameter 
(mm) 
Length 
(mm) 
Abbreviation 
Carbon Medical Technologies  Acculoc Carbon Marker Carbon Cylindrical 1.00 3 Acculoc Carbon (C) 
Naslund Medical AB Gold Anchor Gold Linear 0.28 10 G.A. 10 mm linear (Au) 
Naslund Medical AB Gold Anchor Gold Ball 0.28 10 G.A. 10 mm ball (Au) 
Naslund Medical AB Gold Anchor Gold Linear 0.28 20 G.A. 20 mm linear (Au) 
Naslund Medical AB Gold Anchor Gold Ball 0.28 20 G.A. 20 mm ball (Au) 
RadioMed Corporation/IBA Visicoil Gold Coiled 0.35 10 Visicoil 10 mm (Au) 
Cook Medical EchoTip Ultra Gold Step 0.43 5 Cook Medical (Au) 
Medtronic, Inc. Beacon FNF needle Gold Cylindrical 0.43 5 Beacon FNF (Au) 
Best Medical International, Inc. Loose Gold Marker Gold Cylindrical 0.80 3 Best Medical (Au) 
RadioMed Corporation/IBA Visicoil MR Platinum Coiled 0.35 10 Visicoil 10 mm (Pt) 
RadioMed Corporation/IBA Visicoil MR Platinum Coiled 0.75 5 Visicoil 5 mm (Pt) 
Phantom description  
Fiducials were placed on top of 2-mm Superflab bolus (Mick Radio Nuclear Instruments, Inc., 
Mt. Vernon, NY, USA) and 7-cm Virtual Water (Standard Imaging, Middleton, WI, USA) as 
shown in Figure 1. The fiducials were positioned perpendicular to the longitudinal axis of the 
couch which maximized the volume of each fiducial in a given image slice. An additional 2-mm 
bolus and 6-cm Virtual Water were placed on top of the fiducials before imaging. The 13.4 cm 
thick phantom measured 30 cm by 30 cm. The uniform phantom design facilitates the evaluation 
of artifacts since the images can be split into three regions consisting of fiducial, phantom 
background, and artifacts.  
Figure 1. The uniform bolus and Virtual Water phantom are shown. Markings and in-room lasers were 
used to align the phantom with the imaging system isocenter (A). Two fiducials were placed 3 cm apart 
on top of a 2-mm-thick layer of bolus placed on top of 7 cm of Virtual Water phantom (B). An additional 
2 mm of bolus and 6 cm of Virtual Water were placed on top of the fiducials (C). 
 
 
Imaging modalities and acquisition parameters 
Each of the fiducials were placed within the phantom one at a time and imaged with a 16-slice 
CT simulation scanner (Brilliance Big Bore, Philips Medical Systems, Best, Netherlands), a 
CBCT system (TrueBeam OBI, Varian Medical Systems, Palo Alto, CA, USA), and a 16-slice 
CTOR scanner (GE LightSpeed RT16, GE Healthcare, Waukesha, WI, USA) (15). The phantom 
and fiducials were centered with respect to each imaging system’s isocenter using in-room lasers 
and phantom markings to improve the reproducibility of set-up across each CT acquisition.  
Acquisition parameters were selected for each imaging modality based on institutional protocols 
for GI imaging, as summarized in Table 2. The CTOR exposure level may be adjusted from the 
default value of 84 mAs at the treatment machine, as needed. To investigate the impact of image 
noise on fiducial detectability a second exposure level of 250 mAs was also evaluated for the 
CTOR machine. The x-ray tube potential varied slightly, from 120 to 125 kV. Voxel dimensions 
were comparable across all imaging modalities. Slice thickness ranged from 2.0 mm for the 
CBCT system to 3.0 mm for the CT simulation scanner. Slice thickness is an important 
parameter that impacts the fiducial visibility due to volume averaging and image noise.  
  Table 2 Image acquisition parameters 
Imaging system Scanner type kV mAs 
Slice thickness 
(mm) 
Voxel dimensions 
(mm2) 
Image 
bits 
Philips Brilliance Big Bore CT simulator 120 300 3 0.98 x 0.98 12 
Varian TrueBeam OBI CBCT 125 1074 2 0.91 x 0.91 16 
GE LightSpeed RT16 CT-on-rails 120 84 2.5 0.98 x 0.98 12 
 
Fiducial visibility assessment 
Fiducial visibility was evaluated in terms of contrast (∆𝐻𝑈) and the Michelson visibility metric 
(𝑉). Fiducial contrast was defined as: 
∆𝐻𝑈 =  𝑥𝑓̅̅̅ − 𝑥𝑏̅̅ ̅                      (1) 
Here, ∆𝐻𝑈 represents the signal difference between the mean of image pixel values in a region-
of-interest (ROI) located within the fiducial, 𝑥𝑓̅̅̅, and a nearby background ROI, 𝑥𝑏̅̅ ̅. The ROI, 𝑥𝑓, 
was selected as the 10 mm2 area within the fiducial corresponding to the region of maximum 
intensity. The background ROI, 𝑥𝑏, was located 15 mm from the center-of-mass of the fiducial 
and perpendicular to the long axis of the fiducial in a 20 mm2 region with minimal artifacts. For 
the CTOR machine, the contrast-to-noise ratio (CNR) was computed as CNR = ∆𝐻𝑈/𝜎𝑏, where 
𝜎𝑏 denotes the noise standard deviation in the background ROI, to evaluate fiducial detectability.  
The purpose of the Michelson visibility metric (equation 2) was to quantify contrast in 
terms of the brightest region of the fiducial, independent of fiducial or ROI size. 
𝑉 =  
𝑥𝑚𝑎𝑥 − 𝑥𝑚𝑖𝑛
𝑥𝑚𝑎𝑥 + 𝑥𝑚𝑖𝑛
                  (2) 
Here, 𝑥𝑚𝑎𝑥 represents the maximum signal within a 30 by 30 mm
2 ROI defined about the center-
of-mass of the fiducial, whereas 𝑥𝑚𝑖𝑛 represents the minimum value. Michelson visibility is 
bounded between 0 and 1 with a value of 1 corresponding to maximum visibility.  
Fiducial artifact-level assessment  
The presence of highly attenuating objects such as metal fiducials along x-ray paths traversing 
the object results in photon starvation. After image reconstruction, photon starvation manifests as 
streak artifacts and areas of signal void in regions adjacent to the implanted fiducial.  
Streak artifacts were quantified using the relative streak artifacts level (rSAL) metric 
(16). 
𝑟𝑆𝐴𝐿 =  
|𝑇𝑉(𝑥𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡) − 𝑇𝑉(𝑥𝑟𝑒𝑓)|
𝑇𝑉(𝑥𝑟𝑒𝑓)
                  (3) 
Here, 𝑥𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡 denotes an artifact image, 𝑥𝑟𝑒𝑓 denotes a reference image free of fiducial induced 
artifacts, and 𝑇𝑉(𝑥) is the total variation function. The image 𝑥𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡 was obtained by defining 
a 30 by 30 mm2 square ROI about the center-of-mass of the fiducial and manually segmenting 
the fiducial from the square ROI yielding an image, 𝑥𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡, containing only phantom 
background and artifacts. The reference image, 𝑥𝑟𝑒𝑓, was obtained by imaging the phantom with 
no fiducials present. For consistency, the region corresponding to the fiducial in the image 
𝑥𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡 was also removed from 𝑥𝑟𝑒𝑓. The total variation function, TV(x), was defined as: 
𝑇𝑉(𝑥) = ∑ √(𝑥𝑖+1,𝑗 − 𝑥𝑖,𝑗)2 + (𝑥𝑖,𝑗+1 − 𝑥𝑖,𝑗)2
𝑖,𝑗
                   (4) 
Larger values of TV(x) indicate a higher level of streak artifacts. 
The relative standard deviation (rStdDev), 𝜎𝑟𝑒𝑓
𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡
, was used to further quantify the 
level of artifacts present. 
𝜎𝑟𝑒𝑓
𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡 =  
𝜎𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡
𝜎𝑟𝑒𝑓
                  (5) 
Here, 𝜎𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡 and 𝜎𝑟𝑒𝑓 denote the standard deviations of image values in the artifact image, 
𝑥𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡, and reference image, 𝑥𝑟𝑒𝑓, respectively. For fiducials producing no artifacts, the 
standard deviation of the artifact image, 𝜎𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡, is expected to be comparable to the standard 
deviation of the reference image, 𝜎𝑟𝑒𝑓, free of artifacts. As the artifact level increases, the 
standard deviation of the artifact image is expected to increase, resulting in a larger relative 
standard deviation. Thus, values of 𝜎𝑟𝑒𝑓
𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡
near 1.0 indicate that minimal artifacts are present, 
whereas larger values of 𝜎𝑟𝑒𝑓
𝑎𝑟𝑡𝑖𝑓𝑎𝑐𝑡
 indicate more severe artifacts. 
Survey of fiducial image quality 
Five faculty radiation oncologists and seven radiation oncology residents or fellows each rated 
the 11 different fiducial markers in terms of clinical usefulness. Participants were instructed to 
consider both the fiducial visibility and artifact level as seen on CT simulator and CBCT images 
of each marker placed in the water equivalent phantom. Each radiation oncologist was asked to 
rank each image (22 total) on a scale of 1 to 5 as follows: 1 = not useful at all for clinical 
practice, 3 = acceptable/sufficient for clinical practice, and 5 = ideal for clinical use. The 
differences between mean faculty and resident rankings were assessed by a right-tailed paired 
Wilcoxon signed-ranked test. Statistical significance was defined at the p-value < 0.05 threshold. 
The Pearson correlation coefficient was also reported.  
Results 
Fiducial visibility and artifacts 
Figure 2 presents images of each fiducial acquired with the CT simulator, CBCT, and CTOR 
systems. The images are organized in order of decreasing image contrast (∆𝐻𝑈) for the CT 
simulator. The bar plots present metrics of contrast and artifacts normalized to maximum values 
for the CT simulator images.  
The maximum contrast value was observed for the 0.75-mm-diameter coiled platinum 
fiducial (Visicoil 5 mm) for each of the imaging systems. Figure 2 shows that the fiducial 
contrast and image artifact level increase as the diameter of the fiducial (Table 1) increases, as 
expected, except for the low atomic number carbon fiducial. The minimum contrast value was 
observed for the 0.28-mm-diameter linear-shaped gold fiducials. The contrast of the Gold 
Anchor fiducials was improved when the fiducial was deployed in the ball-like configuration. 
Likewise, a higher level of artifacts may be observed for the ball-like configuration. 
Qualitatively, fewer streak artifacts were present for the carbon and linear gold fiducials.  
The qualitative observations were confirmed by the quantitative image quality metrics 
presented in Table 3. The mean signal difference between the Visicoil 5-mm fiducial and a 
nearby background region measured 2722 HU, 2824 HU, and 4798 HU for the CT simulator, 
CTOR, and CBCT systems, respectively, versus 551 HU, 889 HU, and 865 HU for the Gold 
Anchor 20-mm linear fiducial. The largest rSAL and relative standard deviation were observed 
for the Visicoil 5-mm platinum and Best Medical gold fiducials across all imaging modalities. 
The least severe artifacts were observed, as expected, for the carbon fiducial.  
 
Figure 2. Fiducial markers within a uniform phantom and imaged with a CT simulator, CTOR, and CBCT 
are shown. The bar plots show the contrast and relative streak artifacts level (rSAL) metrics normalized 
to maximum contrast and rSAL for the CT simulator results. The window range is [-500, 1000] HU. 
Abbreviations for the fiducial labels are defined in Table 1. 
 
 
Fiducial rankings for each metric are displayed in parentheses in Table 3. A ranking of 1 
of 11 indicates maximum contrast or minimal artifacts. Conversely, a ranking of 11 indicates 
inferior contrast or a high artifact level. A comparison of rankings will be helpful in selecting a 
fiducial that balances the tradeoff between contrast and artifacts. Of note, the Gold Anchor 10-
mm gold fiducial in a ball-like configuration had an average contrast value of 4.5 of 11 and an 
average artifact level of 5.0 of 11, averaged across the three imaging modalities. This suggests 
that the fiducial design achieved a balance between contrast and artifacts with average metrics 
for both ranking in the top half of the fiducials evaluated. 
Figure 3 presents the CNR of each fiducial imaged as a function of tube exposure for 
CTOR. The CNR increased as the exposure increased from 84 mAs to 250 mAs, as expected, for 
each fiducial. 
Figure 3. The contrast-to-noise ratio is plotted for imaging performed with CT-on-rails at 84 mAs and 
250 mAs for 11 different fiducial configurations. The error bars plotted for the Beacon FNF fiducial 
represent ±1 standard deviation uncertainty estimated from a series of 10 independent measurements 
and phantom set-ups. Abbreviations for the fiducial labels shown in the legend are defined in Table 1. 
 
 
 
Table 3 CT simulator, CT-on-rails, and cone beam CT fiducial contrast and artifacts 
 CT Simulator CT-on-rails Cone-beam CT 
 
Contrast Artifacts Contrast Artifacts Contrast Artifacts 
Fiducial ΔHU Michelson rStdDev rSAL ΔHU Michelson rStdDev rSAL ΔHU Michelson rStdDev rSAL 
Visicoil 5 mm (Pt) 2722    (1) 1.00    (1) 15.6   (11) 2.69  (11) 2824   (1) 1.00    (1) 5.6  (10) 1.68  (11) 4798   (1) 1.00   (1) 7.5   (10) 2.69  (11) 
Best Medical (Au) 2539    (2) 0.94    (2) 11.5   (10) 1.77  (10) 2753   (2) 1.00    (1) 5.8  (11) 1.62  (10) 4723   (2) 1.00   (1) 7.8   (11) 2.42  (10) 
G.A. 10 mm ball (Au) 1903    (3) 0.62    (5) 5.5     (6) 0.78    (6) 2194   (5) 0.72    (5) 2.4    (4) 0.47    (4) 2270   (5) 0.76   (5) 2.7   (6) 0.73    (6) 
Cook Medical (Au) 1898    (4) 0.78    (3) 9.7     (9) 1.68    (9) 2300   (4) 1.00    (1) 4.6    (9) 1.21    (9) 2873   (4) 1.00   (1) 6.5   (9) 1.95    (9) 
G.A. 20 mm ball (Au) 1678    (5) 0.65    (4) 6.5     (7) 0.91    (7) 2621   (3) 1.00    (1) 4.4    (8) 1.08    (8) 2964   (3) 0.84   (4) 4.5   (8) 1.58    (8) 
Beacon FNF (Au) 1266    (6) 0.52    (6) 6.8     (8) 0.97    (8) 1527   (6) 0.72    (6) 2.8    (7) 0.64    (6) 1710   (6) 0.74   (6) 3.5   (7) 0.92    (7) 
Visicoil 10 mm (Au) 1096    (7) 0.36    (7) 4.3     (5) 0.59    (4) 1133   (8) 0.38  (10) 2.4    (5) 0.51    (5) 1379   (7) 0.48   (8) 2.4   (4) 0.51    (5) 
Visicoil 10 mm (Pt) 739      (8) 0.08  (11) 3.5     (3) 0.52    (2) 1253   (7) 0.45    (7) 1.9    (3) 0.46    (3) 1324   (8) 0.37   (9) 2.0   (2) 0.40    (2) 
Acculoc Carbon (C)  628      (9) 0.15    (9) 3.1     (1) 0.29    (1) 923   (10) 0.42    (8) 1.4    (1) 0.20    (1) 998     (9) 0.50    (7) 1.6   (1) 0.33    (1) 
G.A. 10 mm linear (Au) 572   (10) 0.11  (10) 3.9     (4) 0.57    (3) 1071   (9) 0.40    (9) 1.9    (2) 0.35    (2) 946   (10) 0.24  (10) 2.3   (3) 0.49    (4) 
G.A. 20 mm linear (Au) 551   (11) 0.17    (8) 3.3     (2) 0.65    (5) 889   (11) 0.30  (11) 2.6    (6) 0.68    (7) 865   (11) 0.20  (11) 2.6   (5) 0.48    (3) 
Abbreviations:  rSAL = relative streak artifacts level, rStdDev = relative standard deviation. Fiducial abbreviations are defined in 
Figure 1. 
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Survey of fiducial image quality 
Table 4 presents the results from the physician survey of fiducial image quality. The Beacon 
FNF and Visicoil 10-mm gold markers were the two highest-ranked fiducials for both CT and 
CBCT imaging (mean ranking, 4.1 and 4.2, respectively). The Gold Anchor 20-mm fiducial 
marker (linear configuration, mean ranking, 2.1) was ranked the lowest for CT imaging, and the 
Best Medical fiducial (mean ranking, 2.4) was ranked the lowest for CBCT. Physicians preferred 
the Gold Anchor fiducials in the ball-like configuration versus the linear configuration. No 
significant difference was observed between faculty and resident rankings (p-value = 0.36). The 
correlation between mean faculty and resident rankings was 0.76.   
Table 4 Physician survey of fiducial marker image quality results  
  CT-Sim CBCT 
Fiducial μ ± σ Ranking μ ± σ Ranking 
Beacon FNF (Au) 4.3 ± 0.8 1 3.8 ± 0.8 2 
Visicoil 10 mm (Au) 4.3 ± 0.9 2 4.0 ± 1.0 1 
Visicoil 5 mm (Pt) 3.5 ± 1.0 3 2.9 ± 1.2 7 
G.A. 20 mm ball (Au) 3.3 ± 1.1 4 2.6 ± 1.1 8 
G.A. 10 mm ball (Au) 3.0 ± 0.9 5 3.1 ± 0.9 5 
Cook Medical (Au) 2.9 ± 1.3 6 2.6 ± 1.7 8 
Visicoil 10 mm (Pt) 2.9 ± 0.8 6 3.3 ± 1.0 4 
Best Medical (Au) 2.8 ± 1.2 8 2.4 ± 1.3 11 
Acculoc Carbon (C)  2.8 ± 1.3 8 3.4 ± 1.2 3 
G.A. 10 mm linear (Au) 2.4 ± 1.1 10 2.9 ± 1.1 6 
G.A. 20 mm linear (Au) 2.1 ± 0.9 11 2.6 ± 1.0 8 
Abbreviation: CBCT = cone-beam CT. Fiducial abbreviations are defined in Figure 1. 
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Discussion 
This study evaluated the visibility and artifacts of 11 commercially available fiducial markers 
from six different vendors across three different volumetric imaging systems for application to 
image-guided SBRT. The slight difference in atomic number between platinum and gold was 
shown to be less important than fiducial size and other effects such as volume averaging. Carbon 
fiducials presented an alternative option to gold and platinum fiducials, yielding minimal 
artifacts and moderate contrast. An additional benefit of carbon is the reduced dosimetric 
uncertainty relative to gold or platinum making it the preferred fiducial material for proton 
therapy. This work, however, only considered CT and CBCT imaging. Carbon contrast is 
expected to be lower in 2D kV or MV portal images. Additionally, the minimum detectable 
contrast level of carbon markers should be determined in the presence of CBCT streak artifacts.   
Fiducial marker selection for IGRT in the abdomen requires careful consideration of the 
tradeoff between contrast and artifacts as well as awareness of dosimetric uncertainty and 
treatment modality. Image artifacts in CT simulation images may adversely affect the delineation 
of target structures and OARs. Insufficient contrast in CBCT images acquired before treatment 
delivery may increase set-up uncertainty and IGRT accuracy. The quantitative results presented 
in this study will aid the radiation oncologist in optimizing fiducial selection for IGRT. If high 
contrast is prioritized over reduced image artifacts, the results of this study show that one should 
choose the Visicoil 5-mm platinum, Best Medical gold, Cook Medical gold, or Gold Anchor 
(ball-like configuration) fiducials. Conversely, if one favors reduced image artifacts in CT 
simulation images and is willing to accept reduced contrast during IGRT, one ought to choose 
the Gold Anchor (linear configuration), Acculoc carbon, or Visicoil-10 mm platinum fiducials. 
Finally, if one prefers to balance contrast and image artifacts, the Beacon FNF gold or Visicoil 
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10-mm gold fiducials are the best option. 
A survey of 12 radiation oncologists ranked the Beacon FNF gold and Visicoil 10-mm 
gold fiducials highest in terms of clinical usefulness. The Beacon FNF and Visicoil gold 
fiducials were the only fiducials to receive average rankings exceeding 4.0 for CT imaging. Of 
note, the two fiducials preferred in the physician survey were those that balanced contrast and 
artifacts as indicated by the quantitative metrics. The two fiducials receiving the lowest ranking 
for CT imaging were the Gold Anchor 10-mm (2.4 ± 1.1) and 20-mm (2.1 ± 0.9) fiducials 
deployed in a linear configuration. The low physician ranking is validated by the quantitative 
metrics (Table 3) which showed these fiducials demonstrated the lowest image contrast (∆HU). 
In addition to image quality, certain practical aspects must be considered during the 
fiducial selection process. Fiducial selection must include a discussion of the placement-related 
technical challenges, complications, and migration probability unique to each fiducial type. 
Fiducials can be delivered using 19-, 22-, or 25-gauge needles or multifiducial delivery systems. 
The size and shape of the fiducial marker typically dictate the type of needle to be used. 
Fiducials with a broad diameter (>0.75 mm) require a 19-gauge needle for deployment. Studies 
have shown that the use of this needle is feasible and safe; however, its stiffness can compromise 
fiducial placement, especially in challenging anatomic locations or after surgery. In these 
situations, the 19-gauge needle can be replaced with a 22-gauge needle preloaded/backloaded 
with the adequate fiducial marker. 
The probability of fiducial migration must also be considered. Fiducial migration rates 
have been shown to be low; nevertheless, this is an important consideration since migration may 
make the fiducial unusable for IGRT, decrease target coverage, or result in increased dose to 
normal tissue structures (7, 17). A study by Khashab et al. (17) demonstrated a 6.5% fiducial 
18 
 
 
 
migration rate for traditional fiducials versus 3.8% for coiled fiducials; however, the difference 
was not statistically significant. 
Finally, one must consider the patient’s intended treatment modality and likelihood of 
transfer to a different modality during the fiducial selection step. For example, a patient 
originally selected for proton therapy or MR-guided RT may later be transferred to photon-based 
external beam RT. In these instances, one must consider fiducial contrast, artifacts, and 
dosimetric uncertainty for each of the different treatment modalities. 
Several limitations of this work must be acknowledged. First, fiducials were imaged 
within a simple phantom consisting of only bolus and Virtual Water. In a clinical scenario, 
fiducials may be placed near regions containing air or bones that could influence the results of 
this study. Second, object motion was not considered since it was assumed that most GI cancers 
may be treated under the condition of breathhold to minimize respiratory motion. Cone beam CT 
streak artifacts resulting from heterogeneities or motion may reduce fiducial contrast. Future 
studies are required to evaluate the impact of CBCT image artifacts on IGRT accuracy. Third, 
image acquisition parameters were selected based on current clinical protocols. The impact of 
tube potential and exposure time on contrast-to-noise were described previously by Hansfield et 
al (13). In addition to tube parameters, the impacts of image reconstruction parameters, including 
pixel size, algorithm, and metal artifact correction, could be investigated as follow-up work. 
Brook et al. (18) demonstrated that metal artifact reduction software may improve tumor 
visibility near gold fiducial markers. However, Brook et al. focused on spectral CT, which is not 
readily available for RT simulation. Fourth, only a single fiducial orientation was investigated. 
All fiducials were positioned orthogonal (90°) to the longitudinal axis of the couch in order to 
maximize image contrast. To demonstrate the impact of fiducial orientation, the 5-mm platinum 
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fiducial was imaged at different angular orientations corresponding to 0°, 45°, and 90° relative to 
the long axis of the treatment couch. Figure 4 shows that the Michelson contrast and rSAL 
increased as the fiducial rotated from parallel (0°) to perpendicular (90°) to the imaging 
volume’s slice dimension and long axis of the treatment couch. The increase is expected as a 
greater portion of the fiducial is contained within an individual image slice compared with the 
parallel orientation, which increases photon absorption.  
Figure 4. Fiducial relative streak artifacts level (rSAL) and contrast (Michelson) are plotted as a function 
of fiducial orientation. Orientation is defined with 0°, indicating that the long axis of the fiducial is 
parallel to the treatment couch and slice dimension of the image volume. 
 
 
 
 
 
 
 
 
 
Conclusion 
We evaluated 11 commonly used fiducials for image-guided SBRT in terms of visibility and 
artifacts under imaging performed with a CT simulator, CTOR, and on-board CBCT. The results 
will provide useful information when selecting a fiducial type with a preference towards high 
fiducial contrast, low image artifacts, or a balanced tradeoff between contrast and artifacts. A 
survey of radiation oncologists indicated that fiducials balancing image contrast and artifacts are 
preferred. 
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